Novel insights into CB1 cannabinoid receptor signaling: A key interaction identified between the extracellular-3 loop and transmembrane helix 2

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 2, 2013, Pages 189-197

  Marcu, Jahan ^a   Shore, Derek M ^b   Kapur, Ankur ^a   Trznadel, Megan ^a   Makriyannis, Alexandros ^c   Reggio, Patricia H ^b   Abood, Mary E ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; RIMONABANT; TRANSMEMBRANE HELIX 2 PROTEIN; UNCLASSIFIED DRUG; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; BENZOXAZINE DERIVATIVE; CYCLOHEXANOL DERIVATIVE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IMMUNOSUPPRESSIVE AGENT; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; BINDING COMPETITION; CELL LINE; CHEMICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENERGY METABOLISM; METABOLISM; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; RADIOASSAY; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; BENZOXAZINES; BINDING, COMPETITIVE; CELL LINE; CYCLOHEXANOLS; ENERGY METABOLISM; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MORPHOLINES; MUTAGENESIS, SITE-DIRECTED; NAPHTHALENES; PIPERIDINES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84876557408     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201046     Document Type: Article

References (36)

1. Ahn KH, Bertalovitz AC, Mierke DF, and Kendall DA (2009a) Dual role of the second extracellular loop of the cannabinoid receptor 1: Ligand binding and receptor localization. Mol Pharmacol 76:833-842.
2. Ahn KH, Pellegrini M, Tsomaia N, Yatawara AK, Kendall DA, and Mierke DF (2009b) Structural analysis of the human cannabinoid receptor one carboxylterminus identifies two amphipathic helices. Biopolymers 91:565-573.
3. Ahuja S, Hornak V, Yan EC, Syrett N, Goncalves JA, Hirshfeld A, Ziliox M, Sakmar TP, Sheves M, and Reeves PJ, et al. (2009) Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. Nat Struct Mol Biol 16:168-175.
4. Andersson H, D'Antona AM, Kendall DA, Von Heijne G, and Chin CN (2003) Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail. Mol Pharmacol 64:570-577. (Pubitemid 37048559)
5. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, and Christopoulos A (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282: 25677-25686. (Pubitemid 47372845)
6. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in g protein-coupled receptors, in Methods in Neuroscience (Sealfon SC ed) pp 366-428, Academic Press, San Diego, CA.
7. Bertalovitz AC, Ahn KH, and Kendall DA (2010) Ligand binding sensitivity of the extracellular loop two of the cannabinoid receptor 1. Drug Dev Res 71:404-411.
8. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, and Kobilka TS, et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463: 108-112.
9. Bramblett RD, Panu AM, Ballesteros JA, and Reggio PH (1995) Construction of a 3D model of the cannabinoid CB1 receptor: Determination of helix ends and helix orientation. Life Sci 56:1971-1982.
10. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Christopoulou FD and Kiortsis DN (2011) An overview of the metabolic effects of rimonabant in randomized controlled trials: Potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36:10-18.
12. Conner M, Hawtin SR, Simms J, Wootten D, Lawson Z, Conner AC, Parslow RA, and Wheatley M (2007) Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: Key residues, conserved throughout a G-proteincoupled receptor family, identified. J Biol Chem 282:17405-17412. (Pubitemid 47100317)
13. Fay JF, Dunham TD, and Farrens DL (2005) Cysteine residues in the human cannabinoid receptor: Only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44: 8757-8769. (Pubitemid 40840441)
14. Fiser A, Do RK, and Sali A (2000) Modeling of loops in protein structures. Protein Sci 9:1753-1773.
15. Hamm HE, Deretic D, Arendt A, Hargrave PA, Koenig B, and Hofmann KP (1988) Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit. Science 241:832-835.
16. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, and Schuerer SC, et al. (2012) Crystal structure of a lipid G proteincoupled receptor. Science 335:851-855.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, and Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
18. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, and Mackie K (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-3780. (Pubitemid 29222253)
19. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, and Abood ME (2007) Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: Evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71:1512-1524. (Pubitemid 47010904)
20. Kapur A, Samaniego P, Thakur GA, Makriyannis A, and Abood ME (2008) Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther 325:341-348. (Pubitemid 351439160)
21. Li J, Edwards PC, Burghammer M, Villa C, and Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343:1409-1438. (Pubitemid 39387834)
22. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, and Abood ME (2003) An aromatic microdomain at the cannabinoid CB (1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46: 5139-5152. (Pubitemid 37414184)
23. Murphy JW and Kendall DA (2003) Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. Biochem Pharmacol 65:1623-1631. (Pubitemid 36577275)
24. Peeters MC, van Westen GJ, Guo D, Wisse LE, Müller CE, Beukers MW, and Ijzerman AP (2011a) GPCR structure and activation: An essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J 25:632-643.
25. Peeters MC, van Westen GJ, Li Q, and Ijzerman AP (2011b) Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32:35-42.
26. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397-411.
27. Picone RP, Fournier DJ, and Makriyannis A (2002) Ligand based structural studies of the CB1 cannabinoid receptor. J Pept Res 60:348-356. (Pubitemid 36071898)
28. Rana S and Baranski TJ (2010) Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: Implications for an activation microswitch region. J Biol Chem 285:31472-31483.
29. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815. (Pubitemid 24007801)
30. Scarselli M, Li B, Kim SK, and Wess J (2007) Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. J Biol Chem 282:7385-7396. (Pubitemid 47093690)
31. Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA, and Weinstein H (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270:16683-16688.
32. Straiker A, Wager-Miller J, and Mackie K (2012) The CB1 cannabinoid receptor Cterminus regulates receptor desensitization in autaptic hippocampal neurones. Br J Pharmacol 165:2652-2659.
33. Tao Q and Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 298:651-658. (Pubitemid 28237444)
34. Ulfers AL, McMurry JL, Kendall DA, and Mierke DF (2002) Structure of the third intracellular loop of the human cannabinoid 1 receptor. Biochemistry 41: 11344-11350.
35. Xu H, Lu YF, Partilla JS, Zheng QX, Wang JB, Brine GA, Carroll FI, Rice KC, Chen KX, and Chi ZQ, et al. (1999) Opioid peptide receptor studies, 11: Involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands. Synapse 32:23-28. (Pubitemid 29124093)
36. Zhou W, Flanagan C, Ballesteros JA, Konvicka K, Davidson JS, Weinstein H, Millar RP, and Sealfon SC (1994) A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol Pharmacol 45: 165-170. (Pubitemid 24063067)